KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study
- PMID: 30468915
- DOI: 10.1016/j.jgar.2018.11.014
KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study
Abstract
Objectives: KPC-producing Klebsiella pneumoniae (KPC-Kp) gut colonisation is a major risk factor for developing systemic infection. Ceftazidime/avibactam (CAZ/AVI) may have a role as decolonisation therapy in special situations.
Methods: This was a retrospective, observational, multicentre study. The KPC-Kp gut decolonisation rate of CAZ/AVI-based therapy (Group A) was compared with other antimicrobial regimens (Group B) in patients with KPC-Kp infection.
Results: Among 12 patients in Group A, 11 (91.7%) achieved gut decolonisation. None of the 24 patients of Group B were decolonised.
Conclusion: CAZ/AVI-based therapy could be useful in KPC-Kp gut decolonisation in high-risk patients.
Keywords: Carbapenemase-producing Klebsiella pneumoniae; Ceftazidime; Ceftazidime/avibactam; Gut decolonisation; KPC.
Copyright © 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources